Study of Antigenic Activity of Experimental Samples of the Conjugated Vaccines Based on Synthetic Oligosaccharide Ligands and CRM197 Carrier Protein against Candida albicans, Aspergillus fumigatus and Pseudomonas aeruginosa

Abstract:

By now there is no effective treatment for a number of socially significant bacterial and fungal diseases. β-(1→3)-glucans are the principal components of the cell wall of fungi, including Candida albicans, Aspergillus fumigatus and other. At the same time, β-(1→3)-glucans are absent in mammals and man, that makes them promising components of carbohydrate-protein conjugated vaccines for the prevention and treatment of fungal infections. Alginic acid, constructed of β-(1→ 4)-linked mannuronic acid are extracellular polysaccharides produced by Pseudomonas aeruginosa. The protein CRM197 is a non toxic derivative of diphtheria toxin, which is widely used as a safe carrier in conjugated vaccines. The purpose of this study was to investigate the antigenic activity of experimental samples of the conjugated vaccines based on synthetic oligosaccharide ligands and CRM197 carrier protein in the competitive enzyme-linked immunosorbent assay. Two-time immunization Balb/c mice with experimental samples of the conjugated vaccines induced the formation of high titers of specific antibodies. High antibody’s avidity to their oligosaccharide ligands was shown in competitive ELISA. These data suggest the relevance of further preclinical trials of the conjugated antifungal vaccine against Candida and Aspergillus and antibacterial vaccine against Pseudomonas.

• Periodical: Key Engineering Materials (Volume 743)
• Pages: 349-354
• DOI: https://doi.org/10.4028/www.scientific.net/KEM.743.349
• Online since: July 2017
• Authors: Elena G. Bogomolova*, Sergey A. Ishchuk, Olga A. Dobrovolskaya, Ekaterina A. Fedorova, Ilya V. Dukhovlinov, Andrey S. Simbirtsev
• Keywords: Antigen Activity, Aspergillus fumigatus, Balb/c Mice, Candida albicans, Conjugated Vaccines, ELISA, Pseudomonas aeruginosa, Recombinant CRM197

References

[1] Blanchard-Rohner, G. The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age. Vaccine. 31 (2013) 2441–2448.

DOI: 10.1016/j.vaccine.2013.03.036

[2] Zhou, J. Secretory expression of recombinant diphtheria toxin mutants in B. Subtilis. J. Tongji Med. Univ. Tong Ji Yi Ke Xue Xue Bao. 19 (1999) 253–256.

DOI: 10.1007/bf02886955

[3] Retallack, D.M. Reliable protein production in a Pseudomonas fluorescens expression system. Protein Expr. Purif. 81 (2012) 157–165.

DOI: 10.1016/j.pep.2011.09.010

[4] Yashunsky DV, Tsvetkov YE, Grachev AA, Chizhov AO, Nifantiev NE Synthesis of 3-aminopropyl glycosides of linear β-(1→3)-D-glucooligosac-charides. Carbohydrate Research. 419 (2016)1 7.

DOI: 10.1016/j.carres.2015.10.012

[5] Dukhovlinov I.V., Fedorova E.A., Bogomolova E.G., Dobrovolskaya O.A., Chernyaeva E.N., Al-Shekhadat R.I., Simbirtsev A.S. Production of recombinant protein CRM197 in Escherihia coli. Russian journal of infection and immunity. 5 (2015).

DOI: 10.15789/2220-7619-2015-1-37-44

[6] Wang XJ., Sui X., Yan L., Wang Y., Cao YB., Jiang YV. Vaccines in the treatment of invasive candidiasis. Virulence. 6 (2015) 309-315.

[7] Dagan R., Poolman J., Siegrist C. -A. Glycoconjugate vaccines and immune interference: A review. Vaccine. 28 (2010) 5513–5523.

DOI: 10.1016/j.vaccine.2010.06.026

[8] Van den Biggelaar A.H.J. et al. Pneumococcal conjugate vaccination at birth in a high-risk setting: no evidence for neonatal T-cell tolerance. Vaccine. 29 (2011) 5414–5420.

DOI: 10.1016/j.vaccine.2011.05.065

[9] Ito J. I. T cell Immunity and Vaccines Against Invasive Fungal Diseases. Immunological Investigations. 40 (2011) 825–838.

DOI: 10.3109/08820139.2011.595472

[10] Komarova BS, Orekhova MV, Tsvetkov YE, Beau R, Aimanianda V, Latgé JP, Nifantiev NE. Synthesis of a pentasaccharide and neoglycoconjugates related to fungal α-(1→3)-glucan and their use in the generation of antibodies to trace Aspergillus fumigatus cell wall/Chemistry. 21 (2015).

DOI: 10.1002/chem.201405770

[11] Van den Dobbelsteen GP, Faé KC, Serroyen J, van den Nieuwenhof IM, Braun M, Haeuptle MA, Sirena, Schneider J8, Alaimo C, Lipowsky G, Gambillara-Fonck V, Wacker M, Poolman JT. Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal models. Vaccine. 34 (2016).

DOI: 10.1016/j.vaccine.2016.06.067

[12] Yu X1, Wang Y2, Xia Y3, Zhang L2, Yang Q2, Lei J. A DNA vaccine encoding VP22 of herpes simplex virus type I (HSV-1) and OprF confers enhanced protection from Pseudomonas aeruginosa in mice. Vaccine. 34 (2016) 4399-405.

DOI: 10.1016/j.vaccine.2016.07.017